End-of-day quote
Korea S.E.
06:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
4,855
KRW
|
+0.62%
|
|
-2.61%
|
-14.07%
|
Jan. 08 |
CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy
|
MT
| 2023 |
Cha Vaccine Research Institute Co., Ltd. announced that it has received KRW 10 billion in funding from EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.
|
CI
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
293,364
|
131,749
|
151,036
|
Enterprise Value (EV)
1 |
252,660
|
97,624
|
116,467
|
P/E ratio
|
-14.1
x
|
-19.6
x
|
-86
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
587
x
|
734
x
|
514
x
|
EV / Revenue
|
505
x
|
544
x
|
396
x
|
EV / EBITDA
|
-43.3
x
|
-16.1
x
|
-19.8
x
|
EV / FCF
|
-41.9
x
|
-14.4
x
|
-11.4
x
|
FCF Yield
|
-2.39%
|
-6.96%
|
-8.8%
|
Price to Book
|
7.41
x
|
3.95
x
|
4.26
x
|
Nbr of stocks (in thousands)
|
26,429
|
26,429
|
26,732
|
Reference price
2 |
11,100
|
4,985
|
5,650
|
Announcement Date
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net sales
1 |
500
|
179.5
|
294.1
|
EBITDA
1 |
-5,839
|
-6,052
|
-5,886
|
EBIT
1 |
-6,085
|
-6,469
|
-6,419
|
Operating Margin
|
-1,216.93%
|
-3,604.36%
|
-2,182.53%
|
Earnings before Tax (EBT)
1 |
-18,420
|
-6,715
|
-2,103
|
Net income
1 |
-18,420
|
-6,715
|
-1,749
|
Net margin
|
-3,684.01%
|
-3,741.36%
|
-594.82%
|
EPS
2 |
-789.6
|
-254.1
|
-65.72
|
Free Cash Flow
1 |
-6,029
|
-6,799
|
-10,251
|
FCF margin
|
-1,205.81%
|
-3,787.96%
|
-3,485.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
Net Cash position
1 |
40,704
|
34,125
|
34,569
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6,029
|
-6,799
|
-10,251
|
ROE (net income / shareholders' equity)
|
-89.4%
|
-18.4%
|
-5.09%
|
ROA (Net income/ Total Assets)
|
-8.35%
|
-6.4%
|
-7.56%
|
Assets
1 |
220,534
|
104,949
|
23,152
|
Book Value Per Share
2 |
1,499
|
1,262
|
1,325
|
Cash Flow per Share
2 |
150.0
|
90.30
|
221.0
|
Capex
1 |
680
|
447
|
279
|
Capex / Sales
|
135.91%
|
249.27%
|
94.71%
|
Announcement Date
|
3/1/22
|
3/1/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -14.07% | 95.11M | | +5.33% | 111B | | +12.11% | 106B | | -12.56% | 22.24B | | -3.46% | 21.25B | | -5.71% | 18.97B | | -35.21% | 18.52B | | -10.86% | 16.81B | | +37.57% | 12.54B | | -26.24% | 8.09B |
Bio Therapeutic Drugs
|